Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Authors

Stephen J Schuster, University of Pennsylvania
Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Blood

Publication Date

2-29-2024

Volume

143

Issue

9

First Page

822

Last Page

832

Document Type

Open Access Publication

DOI

10.1182/blood.2023022348

Rights and Permissions

Schuster SJ, Huw LY, Bolen CR, Maximov V, Polson AG, Hatzi K, Lasater EA, Assouline SE, Bartlett NL, Budde LE, Matasar MJ, Koeppen H, Piccione EC, Wilson D, Wei MC, Yin S, Penuel E. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 2024 Feb 29;143(9):822-832. doi: 10.1182/blood.2023022348. © 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Schuster, Stephen J; Bartlett, Nancy L; and et al., "Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas." Blood. 143, 9. 822 - 832. (2024).
https://digitalcommons.wustl.edu/oa_4/4530

Additional Links

Supplemental material is available for this article at publisher site.